AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Byline: Kirk Shinkle
A little more than a year ago, First Horizon Pharmaceutical's stock was in the gutter after its line of drugs got beaten out by generic competition. But a new management team and a new line of drugs have revived the company.
Today First Horizon's specialties are cardiovascular and women's health. It's essentially a two-drug firm.
One is Sular, a hypertension drug that came on board in April 2002, when First Horizon bought marketing rights to the drug from AstraZeneca.
The other is Prenate Elite, the leading prenatal vitamin in the U.S. used to metabolize folic acid. The condition affects one in two women in the U.S., says First Horizon Chief Executive Patrick Fourteau.
"Both have more than met our expectations," he said in a second-quarter conference call.
New prescriptions of Sular rose 24% in the second quarter. It brought in $16.3 million.